Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Company Overview - Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment [2] - The company's pipeline includes small molecule drug candidates targeting cancer signaling pathways [2] Key Products and Developments - Ziftomenib is the first investigational therapy to receive Breakthrough Therapy Designation from the U.S. FDA for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML) [2] - A global strategic collaboration with Kyowa Kirin Co., Ltd. was established in November 2024 to develop and commercialize ziftomenib for AML and other hematologic malignancies [2] - Enrollment in a Phase 2 registration-directed trial of ziftomenib for R/R NPM1-mutant AML has been completed, with a New Drug Application submitted in Q2 2025 [2] - KO-2806, a next-generation farnesyl transferase inhibitor, is in a Phase 1 dose-escalation trial for various solid tumors [2] - Tipifarnib is currently in a Phase 1/2 trial in combination with alpelisib for PIK3CA-dependent head and neck squamous cell carcinoma [2] Upcoming Events - Kura Oncology will participate in the Bank of America Securities 2025 Healthcare Conference, with a fireside chat scheduled for May 13, 2025 [1]